The law firm of Federman & Sherwood has initiated an investigation into MiMedx Group, Inc. (NASDAQ: MDXG) (the “Company”) with respect to possible violations of federal securities laws by the Company and its executives. On September 4, 2013, MiMedx’s shares fell 40% to $3.61 and trading was halted after theflyonthewall.com reported that MiMedx received a letter from the Food and Drug Administration (“FDA”) stating that it was and is unlawfully manufacturing drugs. The FDA letter indicated that the Company’s Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing drugs, thereby marketing unapproved biologics products. If you currently own common stock in MiMedx Group, Inc. and purchased your shares before September 4, 2013, have information to assist in our investigation of this transaction, or have any questions or concerns regarding this notice or preservation of your rights, please contact William B. Federman. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.